Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. (NYSE: NXTC) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for cancer and immune disorders. This page provides centralized access to official news and developments surrounding their innovative pipeline, including antibody-drug conjugates and fusion protein therapies targeting complex tumor microenvironments.
Investors and researchers will find timely updates on clinical trial progress, strategic collaborations, and regulatory milestones. Key focus areas include NC410 combination therapies for immune modulation and the B7-H4-targeting LNCB74 ADC program. The curated news collection also covers financial disclosures, manufacturing advancements, and scientific presentations.
All content is sourced directly from company releases and verified industry publications. Bookmark this page to monitor NextCure's progress in developing first-in-class immunomedicines and their expanding research into neurodegenerative and chronic disease applications.
NextCure announced preclinical data showing that NC605, their anti-Siglec-15 antibody, enhanced quality bone generation with improved mechanical properties in mice with Osteogenesis Imperfecta (OI). The study used NP159, a surrogate antibody to NC605, at 20 mg/kg dosage. Key results showed 90% of male and 80% of female treated mice had no fractures, compared to 85% and 55% in control groups. Both sexes demonstrated increased trabecular and cortical tissue mineral density. Male mice specifically showed increased trabecular bone volume and cortical thickness, resulting in improved mechanical bone strength.
NextCure has provided a business update and reported its third-quarter 2024 financial results. The company is focusing on LNCB74 (B7-H4 ADC) with a planned IND submission by year-end and aims to advance into Phase 1 trials. NextCure's cash reserves of approximately $75 million are expected to fund operations into the second half of 2026. The NC410 combo trial showed encouraging results in ovarian cancer and CRC patients but will conclude as the company seeks a partner for further development. Financially, NextCure's cash and equivalents decreased from $108.3 million to $75.3 million in 2024, primarily due to operational expenses. R&D expenses dropped to $8.8 million from $11.0 million, and G&A expenses decreased to $3.7 million from $4.6 million. The net loss for the quarter was $11.5 million, down from $14.3 million in the same period in 2023.
NextCure (NXTC) presented preclinical data for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC), and additional biomarker data for NC410 combination therapy at SITC. LNCB74 showed promising results with strong anti-tumor activity in multiple tumor models and favorable safety profile, with IND filing expected by year-end. The NC410/pembrolizumab combination demonstrated clinical activity in MSS/MSI-L colorectal cancer patients, achieving 3 partial responses among 43 evaluable patients and disease control rates of 86% and 47% at 200mg and 100mg doses, respectively. Biomarker data supported NC410's mechanism of action in remodeling tumor microenvironment.
NextCure Inc (Nasdaq: NXTC) announced two presentations at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Houston, TX from November 6-10, 2024. The company will present:
1. Pre-clinical data on LNCB74, a B7-H4 antibody-drug conjugate, in a poster session on November 8.
2. Biomarker data from the NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L colorectal cancer, in a poster session on November 9.
These presentations showcase NextCure's ongoing research in novel cancer therapies, particularly in antibody-drug conjugates and combination immunotherapies.
NextCure (Nasdaq: NXTC) presented clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab at ESMO 2024. The trial demonstrated clinical activity in hard-to-treat cancers, including ovarian cancer and immune checkpoint inhibitor (ICI) naïve microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC).
Key results include:
- 5 partial responses (PRs) out of 20 evaluable ovarian cancer patients
- 3 PRs out of 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis
- Biomarker data supporting the proposed mechanism of action of NC410
The combination showed durable responses in both tumor types, which are generally unresponsive to immunotherapy. NextCure plans to provide an update on patients remaining in the study later this year.
NextCure (Nasdaq: NXTC) provided a business update and reported Q2 2024 financial results. Key highlights include:
1. Completed enrollment of 16 additional ovarian cancer patients in the NC410 + pembrolizumab Phase 1b study.
2. Finished GLP toxicology studies for LNCB74 (B7-H4 ADC), targeting IND submission by year-end.
3. Cash position of $86.4 million, expected to fund operations into H2 2026.
4. Q2 2024 financials: R&D expenses $12.4M, G&A expenses $4.1M, net loss $15.4M.
5. On track to present expanded ovarian cancer cohort data and CRC update in Q4 2024.
6. Advancing NC181 (APOE4) and NC605 (Siglec-15) programs, seeking partnerships for IND filings.
NextCure, a clinical-stage biopharmaceutical company listed on Nasdaq as NXTC, has announced its participation in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference.
The event is scheduled for June 27, 2024. NextCure will present and host meetings with institutional investors.
A recording of the webcast will be accessible starting at 7 AM ET on the same day through the Investors section of NextCure’s website, www.nextcure.com, and will remain available for 30 days.
NextCure (Nasdaq: NXTC) announced promising results from its Phase 1b study of NC410 in combination with pembrolizumab, presented at ASCO 2024. The study focused on patients with MSS/MSI-L colorectal cancer (CRC) and ovarian cancer. Key findings include a 51% disease control rate in CRC patients and a 43% rate in ovarian cancer patients. Two CRC patients had ongoing partial responses (PR) and a median disease control duration of 5.5 months. In ovarian cancer, three patients experienced PRs with a 43% overall response rate. Adverse events were mostly mild, but 39.5% of patients had Grade ≥3 Treatment Emergent Adverse Events (TEAE), and 4.9% had Grade ≥3 Treatment-Related Adverse Events (TRAE). A poster presentation by Dr. Eric S. Christenson will detail these findings on June 1, 2024, at the ASCO Annual Meeting in Chicago.
NextCure, a clinical-stage biopharmaceutical company, reported its first-quarter 2024 financial results and provided a business update. They highlighted presenting Phase 1b data for NC410 combo with pembro at the ASCO Annual Meeting, showcasing preclinical data from LNCB74 at the AACR Annual Meeting, and having cash of approximately $96.0 million to fund operations into the second half of 2026. The company is focused on developing novel cancer therapies.
FAQ
What is the current stock price of Nextcure (NXTC)?
What is the market cap of Nextcure (NXTC)?
